ESMO 2022 | Unanswered questions of interest from the LITESPARK-004 trial

Ramaprasad Srinivasan, MD, PhD, National Cancer Institute, Bethesda, MD, describes questions that were not addressed during the Phase II LITESPARK-004 study (NCT03401788), which assessed the efficacy and safety of belzutifan, a HIF-2α inhibitor, in patients with Von Hippel-Lindau (VHL) syndrome. Whilst the drug was effective at targeting renal and central nervous system (CNS) tumors, the trial did not clearly evaluate the efficacy of belzutifan in eye tumors. Additional questions remain regarding how long the drug should be administered for as well as if there are strategies to prevent new tumors from forming. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.